Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES).
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. A lower dose of 20 mg orally may be used for some patients.
* **Pathological hypersecretory conditions (ZES):** Start with 40 mg orally or intravenously twice daily. Doses may be increased as needed. Doses up to 240 mg daily have been administered intravenously.
## Pediatric Dosing
* **GERD:**
* 1 year to 5 years: 10 mg orally once daily for up to 8 weeks.
* 5 years to 16 years: 20 mg orally once daily for up to 8 weeks.
* Dosing for healing of erosive esophagitis in children 5 to 16 years is 40 mg orally once daily for up to 8 weeks.
* *Note: Dosing for neonates and infants younger than 1 year is not established.*
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose of 40 mg orally. IV dose should not exceed 40 mg daily.
* **Renal Impairment:** No dose adjustment needed.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness.
* **Serious:** Fundic gland polyps (long-term use), Clostridioides difficile-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia, vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, mycophenolate mofetil. PPIs can decrease absorption. Separate administration times.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider PPI discontinuation during methotrexate treatment if possible.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Monitor for potential drug interactions with substrates like clopidogrel, though clinical significance is debated.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, seizures, arrhythmias), especially with prolonged use (more than 3 months).
* Monitor for bone mineral density if risk factors for osteoporosis are present.
* Monitor for gastrointestinal symptoms.
## Clinical Pearls
* Pantoprazole is generally considered less likely to interact with clopidogrel compared to omeprazole or esomeprazole, although caution is still advised.
* IV pantoprazole is typically reconstituted and further diluted for infusion. Follow manufacturer or local protocol for preparation and administration.
* Long-term PPI use is associated with increased risk of C. difficile infection, bone fractures, and vitamin B12 deficiency.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date details.
